EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors

Chenlin Ye, Nan Jiang, Jing Zheng, Shumeng Zhang, Jingchen Zhang, Jianya Zhou

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-03 · 1879 (2) · 189066

DOI: 10.1016/j.bbcan.2023.189066 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-03. Verfasst von Chenlin Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 129 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Decitabine's early successful therapeutic outcomes in hematologic malignancies have led to regulatory approvals from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for addressing myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These approvals have sparked keen interest in exploring the potential of decitabine for treating solid tumors. Continuous preclinical and clinical trials have proved that low doses of decitabine also bring benefits in treating solid tumors, and various proposed mechanisms attempt to explain the potential efficacy. It is important to note that the application of decitabine in solid tumors is still considered investigational. This article reviews the application mechanism and current status of decitabine in the treatment of solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteUnited StatesHumansDecitabineAzacitidineEpigenesis, Genetic

Stichwörter der Autor:innen

DecitabineEpigenetic therapySolid tumor

Substanzen

DecitabineAzacitidine

Autor:innen und Institutionen

  • Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Critical Care Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Electronic address: zhoujy@zju.edu.cn.

Zitieren

APA

Ye, C., Jiang, N., Zheng, J., Zhang, S., Zhang, J., & Zhou, J. (2024). Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(2), 189066. https://doi.org/10.1016/j.bbcan.2023.189066

Vancouver

Ye C, Jiang N, Zheng J, Zhang S, Zhang J, Zhou J. Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(2):189066. doi:10.1016/j.bbcan.2023.189066

BibTeX
@article{Ye2024,
  author = {Ye, Chenlin and Jiang, Nan and Zheng, Jing and Zhang, Shumeng and Zhang, Jingchen and Zhou, Jianya},
  title = {Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2024},
  volume = {1879},
  number = {2},
  pages = {189066},
  doi = {10.1016/j.bbcan.2023.189066}
}
Kostenlos starten →